Genetic Technologies Stock Fundamentals
| GENE Stock | USD 0.77 0.00 0.00% |
Genetic Technologies fundamentals help investors to digest information that contributes to Genetic Technologies' financial success or failures. It also enables traders to predict the movement of Genetic Stock. The fundamental analysis module provides a way to measure Genetic Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genetic Technologies stock.
At present, Genetic Technologies' Total Other Income Expense Net is projected to decrease significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 3.9 M, whereas Total Revenue is forecasted to decline to about 5.3 M. Genetic | Select Account or Indicator |
Genetic Technologies Company Profit Margin Analysis
Genetic Technologies' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genetic Technologies Profit Margin | (1.24) % |
Most of Genetic Technologies' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Genetic Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Genetic Technologies has a Profit Margin of -1.2424%. This is 88.92% lower than that of the Life Sciences Tools & Services sector and 89.3% lower than that of the Health Care industry. The profit margin for all United States stocks is 2.17% lower than that of the firm.
Genetic Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genetic Technologies's current stock value. Our valuation model uses many indicators to compare Genetic Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genetic Technologies competition to find correlations between indicators driving Genetic Technologies's intrinsic value. More Info.Genetic Technologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Genetic Technologies' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Genetic Technologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Genetic Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.Genetic Technologies is currently under evaluation in profit margin category among its peers.
Genetic Technologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Genetic Technologies from analyzing Genetic Technologies' financial statements. These drivers represent accounts that assess Genetic Technologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Genetic Technologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 19.9M | 65.3M | 26.4M | 19.4M | 10.2M | 9.7M | |
| Enterprise Value | 6.1M | 44.6M | 15.4M | 12.1M | 10.1M | 9.6M |
Genetic Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 3.6 M | ||||
| Shares Outstanding | 4.85 M | ||||
| Shares Owned By Institutions | 1.10 % | ||||
| Number Of Shares Shorted | 25.84 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 3.11 X | ||||
| Price To Sales | 0.38 X | ||||
| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Cash And Equivalents | 11.74 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 875.19 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Short Ratio | 2.32 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 55 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 3.71 M | ||||
| Total Asset | 6.19 M | ||||
| Retained Earnings | (166.38 M) | ||||
| Working Capital | (500.09 K) | ||||
| Current Asset | 9.03 M | ||||
| Current Liabilities | 992 K | ||||
| Net Asset | 6.19 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 741.6 K | 378.3 K | |
| Total Revenue | 7.7 M | 5.3 M | |
| Cost Of Revenue | 3.8 M | 3.9 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 1.33 | 1.27 | |
| Research And Ddevelopement To Revenue | 0.10 | 0.09 | |
| Revenue Per Share | 0.06 | 0.05 | |
| Ebit Per Revenue | (0.85) | (0.90) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:Check out Genetic Technologies Piotroski F Score and Genetic Technologies Altman Z Score analysis. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 2.19 | Quarterly Revenue Growth (0.11) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.